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Abstract
Background: Cesarean delivery has already become a very common method of delivery around the world,
especially in low-income countries. Hypertrophic scars and wound infections have affected younger mothers and
frustrated obstetricians for a long time. Mesenchymal stem cells (MSCs) have strong potential for self-renewal and
differentiation to multilineage cells. Previous studies have demonstrated that MSCs are involved in enhancing
diabetic wound healing. Therefore, this study is designed to investigate the safety and efficacy of using MSCs in the
treatment of Cesarean section skin scars.
Methods: This trial is a prospective, randomized, double-blind, placebo-controlled, single-center trial with three
parallel groups. Ninety eligible participants will be randomly allocated to placebo, low-dose (transdermal hydrogel
MSCs; 3 × 106 cells) or high-dose (transdermal hydrogel MSCs; 6 × 106 cells) groups at a 1:1:1 allocation ratio
according to a randomization list, once a day for six consecutive days. Study duration will last for 6 months,
comprising a 1 week run-in period and 24 weeks of follow-up. The primary aim of this trial is to compare the
difference in Vancouver Scar Scale rating among the three groups at the 6th month. Adverse events, including
severe and slight signs or symptoms, will be documented in case report forms. The study will be conducted at the
Department of Obstetric of Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan.
Discussion: This trial is the first investigation of the potential for therapeutic use of MSCs for the management of
women’s skin scar after Cesarean delivery. The results will give us an effective therapeutic strategy to combat
Cesarean section skin scars, even with uterine scarring.
Trial registration: ClinicalTrials.gov, NCT02772289. Registered on 10 May 2016.
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Background
Over the past decades, Cesarean delivery has already
become a very common method of delivery around the
world, especially in low-income countries [1]. In China,
although the Cesarean rate has decreased in individual
megacities, the overall annual rate has still increased,
reaching 34.9% in 2014, from 28.8% in 2008 [2]. Hyper-
trophic scars and wound infections have affected
younger mothers and frustrated obstetricians for a long
time. As one of the top three hospital-acquired infec-
tions, wound infections can prolong hospitalization and
greatly increase the rates of hospital readmission, risk of
death, and overall costs of healthcare [3]. It is reported
that the incidence of wound infections ranges from 3%
to 20% in women after Cesarean delivery [4]. In addition,
hypertrophic scars and psychological stress are causes of
dissatisfaction in women after Cesarean delivery.
The cutaneous wound healing process is very complex.
It requires a variety of cells to collaborate, such as resi-
dent cells of the skin, hematopoietic cells, and immune
cells [5]. Many complex factors, such as abnormal
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macrophage polarization, abnormal keratinocyte and
fibroblast migration, proliferation, differentiation and
apoptosis, impaired recruitment of mesenchymal stem
cells (MSCs) and endothelial progenitor cells, and
decreased vascularization may contribute to an abnor-
mal wound healing process [6–8]. It is also reported that
enhanced and prolonged expression of tumor necrosis
factor-alpha contributes to abnormal wound healing
processes [9, 10].
Hypertrophic scarring is a fibrotic disease, arising
from fibroproliferation disorder, which occurs after
the damage of the deep dermis by deep skin injury,
surgical procedure, or burns [11]. Overproduction of
extracellular matrix and collagens are considered to
be the main pathological characteristics of hypertrophic
scars [12, 13]. Key cell subpopulations, including deep der-
mal fibroblasts, myofibroblasts, fibrocytes, and T-helper
cells, could both modify and interact with the extracellular
matrix of the wound, ultimately forming a hypertrophic
scar [14]. Abnormal wound healing processes can also
cause bacterial proliferation. In some instances, the bac-
terial load increases sufficiently for infection to ensue [15].
Therefore, an abnormal wound healing process could
increase the risk of hypertrophic scarring and wound
infection. In turn, continuous inflammation and bacterial
proliferation also increase the risk of abnormal wound
healing processes.
Post-Cesarean wound infection has been ascribed to
many factors, including obstetrician-related factors, such
as skin incision type, time of operation, suture technique,
or intraoperative blood loss, and maternal factors, such as
intrauterine infection prior to delivery, presence of comor-
bidities, or body mass index [16, 17]. Antibiotics, wound
exploration, and debridement are mainstays in the medical
care of post-Cesarean wound infections at present [18].
Many therapeutic approaches, such as laser therapy, radi-
ation, cryotherapy, cryosurgery, or intralesional injections
of corticosteroids, have also been reported in the manage-
ment of hypertrophic scars [19]. However, many of them
are involved in high rates of recurrence, and many are also
expensive and painful.
Mesenchymal stem cells are a population of pluripo-
tent stem cells. They possess high potencies of self-
renewal and differentiation into canonical cells of the
mesenchyme [20]. They are initially discovered in bone
marrow and are subsequently found in almost every type
of tissue, including the endometrium, placenta, umbilical
cord, adipose tissue, and gingiva [21]. They have been
reported as an effective and successful treatment for
many diseases, including rheumatoid arthritis [22],
experimental autoimmune encephalomyelitis [23], bone
regeneration [24], and ischemic cardiomyopathy [25]. As
a treatment modality, MSCs have demonstrated great
potential value.
Through their migratory, anti-inflammatory, and
trophic properties, MSCs exert numerous functions that
may be of relevance for restoring skin tissue function
and enhancing healing [26]. Using a rabbit model,
researchers found that human MSCs can regulate
inflammation and prevent the formation of hypertrophic
scars [27]. Previous results of clinical trials also demon-
strated the benefits derived by the employment of MSCs
in wound healing [28, 29]. Falanga et al. [30] indicated
that MSCs can be safely and effectively delivered to
wounds using a fibrin spray system. Another clinical trial
showed that directly applied bone marrow-derived cells
can lead to dermal rebuilding and closure of nonhealing
chronic wounds [31]. Yoshikawa et al. [32] demon-
strated that MSCs are therapeutically effective in
patients with intractable dermatopathies. In addition,
Dash et al. [33] showed that autologous implantation of
bone marrow-derived MSCs in nonhealing ulcers accel-
erated the healing process and significantly improved
clinical parameters.
In this trial, we hypothesize that MSCs can reduce
hypertrophic scars and decrease wound infection after
Cesarean delivery. Therefore, we undertake a Phase II
clinical trial to evaluate the safety and efficacy of MSCs
in the treatment of Cesarean section skin scars in a pro-
spective, randomized, double-blind, placebo-controlled,
single-center study.
Methods
Study design
This study protocol conforms to the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) guidelines (see Fig. 1 and Additional file 1).
The trial is intended to target primiparous women
between the 37th and 42nd weeks of gestation. Trained
out-patient doctors will introduce the details of the trial
to each potential participant during a clinic visit. The
trial coordinator will contact the interested participant
by mobile phone and WeChat, a very popular social net-
working app in China [34]. Eligible participants will be
introduced in the trial. The inclusion and exclusion
criteria and trial flow are shown in Table 1 and Fig. 2,
respectively. The selection, information process, and
randomization will be implemented as soon as we know
that the primiparous woman is going to have a pro-
grammed Cesarean delivery. There is about 1 day
between selection and delivery. The Cesarean delivery
will be programmed for a gestational age ≥ 37 weeks and
< 42 weeks. This trial will be a prospective, randomized,
double-blind, placebo-controlled with three parallel
groups. The trial will be conducted at the Department of
Obstetric of Southern Medical University Affiliated
Maternal & Child Health Hospital of Foshan.
Fan et al. Trials  (2018) 19:155 Page 2 of 8
Interventions
Eligible participants, who have signed informed consent
forms, will be randomized to placebo, low-dose (3 × 106
cells) or high-dose (6 × 106 cells) groups, receiving trans-
dermal hydrogel MSCs or placebo once a day for six
consecutive days. Each pump dispenses 1.0 ml gel (in-
cluding 1 × 106 cells or none). The justification of doses
is based on previous studies for other indications [35,
36] and our preliminary experiment (unpublished). Each
pump, either MSCs or placebo, has the same external
characteristics except for a digital tag, to allow blinding
of the intervention. After suturing the skin incision as
usual, the first intervention will take place on the operat-
ing table and the remaining five interventions will take
place in the postnatal ward. Participants in the placebo
group will receive placebo hydrogel once a day for 6
days; those in the low-dose group will receive one dose
of hydrogel with cells once a day for three consecutive
days and then placebo hydrogel for the next three con-
secutive days; those in the high-dose group will receive
cells for 6 days.
The government has been committed to promoting
cooperation between governments, academia, pharma-
ceutical companies, biotechnology firms, and private
investors to research and evaluate MSC therapies, since
they are advanced therapies [37, 38]. The Health-Biotech
Pharmaceutical Company (Beijing, China) manufactures
both MSCs and the placebo hydrogel. The products will
be provided without charge. The MSCs are extracted
from the umbilical cord, which is donated by a healthy
donor who has provided informed consent. Detailed
descriptions of the method have been given in a previous
article [39].
The study duration will last for 6 months, including a
1 week run-in period and 6 months of follow-up. All
participants will be assessed at 0.5, 1, 3, and 6 months
during the follow-up period. Table 2 provides the time
Fig. 1 SPIRIT figure
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Primiparous women receiving
Cesarean delivery
Any systemic uncontrolled
disease
Aged 21–35 years Recent or current cancer
Gestation age ≥ 37 weeks
and < 42 weeks
History of or presenting
with a keloid formation
Willing to sign an informed
consent form and a photographic
release form
Wounds or local disease
in treatment area
Willing to comply with study
dosing and complete entire
course of study
Planning any other cosmetic
procedure to the study area
during the study period
Smoking
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points and specific measurements of data. Cosmetic use
may affect wound function. If participants use cosmetics
in the follow-up period, they will be withdrawn from the
study.
Outcomes
Primary outcome
The primary aim of this study is to compare the differ-
ence in Vancouver Scar Scale (VSS) rating among the
three groups in the 6th month. The VSS rates vascularity
(normal, pink, red, or purple), pigmentation (normal,
hypopigmented, mixed, or hyperpigmented), height (flat,
< 2 mm, 2–5 mm, or > 5 mm), and pliability (normal,
supple, yielding, firm, ropes, or contracture). The
Chinese version of the VSS has been shown to have
good intraclass correlations and Cronbach’s α measures
[40, 41]. All scars will be assessed independently by two
observers (SW and SY) on the same day when the
participants are lying in a supine position with the scar
exposed in bright light. If the data varies, another
researcher (DF) will be required to assess the scar at the
same day and the results with the highest frequency will
be recorded.
Secondary outcomes
The secondary outcome measures are as follows:
1) The VSS at 1 and 3 months after treatment
The VSS will be also evaluated at 1 and 3 months
after treatment. The differences in the 1st and 3rd
month will also be compared among the three groups.
2) Wound healing
Wound healing status will be assessed 14 days
after surgery using the REEDA scale. The REEDA
scale contains five variables: redness, edema,
ecchymosis, discharge, and the approximation of
wound edges [19].
3) Erythema and pigmentation
These will be measured using a narrowband
reflectance spectrophotometer (Mexameter MX18)
at 1, 3, and 6 months after treatment.
Table 2 Schedule of visits and assessments
Time point (weeks) 2 4 12 24
Vancouver Scar Scale √ √ √
REEDA scale √
Erythema √ √ √
Pigmentation √ √ √
Scar thickness √ √ √
Scar area √ √ √
Immunoglobulin √ √ √
Satisfaction √ √ √
Adverse events √ √ √ √
REEDA, Redness, Edema, Ecchymosis, Discharge, Approximation
Fig. 2 Trial schema
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4) Scar thickness and area
The scar thickness and area will be measured using
a high definition ultrasound device at 1, 3, and 6
months after treatment.
5) Meanwhile, the mother’s milk will be collected at
each visit and immunoglobulins (IgG, IgA, IgM) and
complements (C3, C4) will be detected by the
transmission immune turbidity method using an
automatic biochemical analyzer.
6) Participants’ satisfaction of the treatment will be
measured using a satisfaction scale, including five
categories, namely, none, slight, moderate, good, and
very good.
7) The number of hypertrophic scars and wound
infections during the 6 months.
8) Safety and tolerability of the intervention.
All adverse events, including side effects and other
ailments, will be recorded in a case report form. The
researcher will report all adverse events to the ethics com-
mittee. For all participants, additional services arising
from all adverse events will be provided free of charge.
Sample size
Our sample size calculation is based on previous results
from Professor Yu-Chen Huang’s preliminary trial in
Taipei Medical University WanFang Hospital [42]. These
results found that the mean VSS was 4.50 ± 1.68 in
healthy pregnant women. The ratio of the MSC and
control group sample size sets was 2:1. We will use the
conventional values α = 0.05 and β = 0.1 for two-sided
tests of probability. Meanwhile, we hypothesize that the
difference in mean VSS at 6 months after treatment
between the MSCs and placebo group will be δ = 1.5.
The total sample size is estimated to be 74. Considering
a dropout and other potential influencing factors, the
final participant is estimated to be about 90 (n = 30 in
each group).
Randomization, concealment, and blinding
A computerized random number generator will be used
to produce a randomization schedule employing simple
randomization by an independent clinical researcher,
who is not involved in the recruitment, intervention, as-
sessment, or statistical analysis. During the study period,
the independent clinical researcher will retain the
randomization list. The randomization sequences will be
concealed in lightproof, sealed envelopes. After signing
informed consent forms, eligible participants will be ran-
domly allocated to the three parallel groups at a 1:1:1
allocation ratio, according to the randomization list.
Each participant will receive a unique randomized
number. Meanwhile, each participant’s pump will be
labeled with a unique randomization number, which will
become the participant’s number. Direct participants
and investigators, including the outcome assessors and
statisticians, will be blinded to the allocation status
throughout the study. Once participants have been allot-
ted randomized numbers, a reasonable effort will be
made by investigators to avoid missing data.
Data collection and management
All research investigators will be trained uniformly in
standard operating procedures. A regular monitoring
scheme will be set up to collect accurate and valid data.
Non-numeric data will be converted into numbers for
storage. All laboratory specimens will be identified only
by a coded identification number to maintain participant
confidentiality. To ensure confidentiality, data dispersed
to project team members will be blinded to any identify-
ing participant information. After verification of the con-
tent, two research investigators will independently input
the data into a database. All participant information will
be kept safely under confidential conditions and
archived for 10 years. The project principal investigator
could access the full data. Participant recruitment is
currently in progress. The first participant was recruited
on 14 September 2016.
Meanwhile, a data monitoring committee will be
established, which will be independent of the study orga-
nizers and will periodically review the accumulating data
and determine whether the trial should be modified or
discontinued. The committee members will perform in-
dependent review of trial processes every 2 months.
Statistical analysis
All analyses will be conducted on the intention-to-treat
and per-protocol principles. Regardless of whether par-
ticipants received the randomized treatment, the
intention-to-treat principle considers all of them as ran-
domized. A complete case analysis will be performed if
missing data for the randomized participants accounts
for less than 5% of total data. Multiple imputations will
be used if missing data is more than 5%. Dropouts will
be included in the analysis by multiple imputations for
missing data. The effect that the per-protocol partici-
pants and missing data might have on results will be
assessed via sensitivity analysis. Subgroup analysis will
be performed based on age and gestational age.
The primary comparison, both doses vs. placebo, will
be analyzed using a superiority analysis. We will use the
t test for the continuous outcome. Meanwhile, high dose
vs. placebo and low dose vs. placebo will also be ana-
lyzed using the t test. Other outcomes will be analyzed
using noninferiority analysis. The mean (and standard
deviation) will be expressed for continuous variables,
and numbers (percentages) will be expressed for categor-
ical variables. Group variances will be compared using
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Leven’s test at the 0.05 significance level. Analysis of
variance (ANOVA) will be used to analyze continuous
data, and the chi-square test or Fisher’s exact test will be
used for categorical data. To investigate the effects of
treatment and time course, repeated measures ANOVA
will be applied to determine changes in the continuous
outcome data at each visit. R 3.1 software will be used
for analysis.
Discussion
Mesenchymal stem cells have a strong potential for self-
renewal and differentiation to multilineage cells. They
can secrete several extracellular matrix molecules,
growth factors, and cytokines that play a pivotal role in
the regulation of angiogenesis and immune and inflam-
matory responses [19, 43]. Currently, several clinical tri-
als have found potential value in using MSCs in healing
chronic and acute wounds and scar remodeling [44].
To assess the efficacy and feasibility of autologous
bone marrow-derived MSCs in the treatment of chronic
nonhealing ulcers, researchers designed a randomized
control study on a series of 24 participants with a history
of nonhealing leg ulcer [33]. After 12 weeks, compared
with control participants, the treatment participants had
significant improvement in reduction in ulcer size. These
results indicated that autologous implantation of bone
marrow-derived MSCs in nonhealing ulcers accelerated
the healing process. A single-arm clinical trial also
indicated that autologous MSCs were shown to be thera-
peutically effective in patients with skin wounds [32]. To
identify better cells for the treatment of diabetic foot
ulcers, a randomized controlled trial was conducted on a
sample of 41 type 2 diabetic patients with bilateral foot
ulcer [45]. All patients were injected intramuscularly
with bone marrow MSCs, bone marrow-derived mono-
nuclear cells, or normal saline as placebo. They found
that bone marrow mesenchymal stem cell therapy might
be more effective than bone marrow-derived mono-
nuclear cell therapy in promoting foot ulcer healing in
diabetic patients. Another similar randomized controlled
trial also obtained a similar result [46]. The frequency of
major limb amputation was lower in a group treated
with autologous bone marrow stem cells than in a group
receiving standard medical care. Meanwhile, a meta-
analysis demonstrated that autologous stem cell trans-
plantation can be considered a safe and effective
approach for treatment of many patients with diabetes
mellitus [47].
Although previous results of trials with MSCs in
wound healing have been reported, the application of
MSCs on Cesarean section skin scars has not yet been
investigated. In this prospective, randomized, double-
blind, placebo-controlled study, we aim to investigate
the possible effects of MSCs in women’s skin scars after
Cesarean delivery. We hypothesize that MSCs can
enhance wound healing, reduce hypertrophic skin scars,
and decrease wound infection. To our knowledge, this
trial is the first to investigate the potential of the thera-
peutic use of MSCs for the management of women’s skin
scars after Cesarean delivery. The outcomes from this
trial will help to determine the efficacy and safety of
MSC treatment in Cesarean section skin scars. The
results will also identify a therapeutically effective dose
of MSCs in preventing hypertrophic scars and wound
infections risk factors. It will give us an effective thera-
peutic strategy to combat Cesarean section skin scars,
even with uterine scarring.
A limitation of this trial is that this is a single-center
clinical trial, which will limit the extrapolation of results.
Meanwhile, loss of participants at follow-up is possible,
especially for nonresponders in the prospective trial
study. Notwithstanding its limitations, this trial will
suggest whether MSC can be a safe and effective in the
treatment of Cesarean section skin scars.
Trial status
Participant recruitment is currently in progress. The first
participant was recruited on 14 September 2016. We hope
to complete enrolment for the trial by March 2018 with
all 6 month follow-up data expected by September 2018.
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